| Metric | Value ($ M) | Q1 FY26 |
|---|---|---|
| Revenue | 81.17 | 12.5% |
| Total Income | 81.17 | 12.5% |
| Expenditure | 103.28 | 9.0% |
| PBT | -14.71 | 64.3% |
| Net Profit | -14.58 | 64.9% |
| OPM | -27.24% | 4.12pp |
| NPM | -17.96% | 39.61pp |
| EPS | -0.03 | 86.4% |
Canopy Growth Reports Q1 FY2027 Financial Results with 13% Net Revenue Growth
07 Aug 2026 · 7 Aug, 4:42 pm
Summary
Canopy Growth Corporation announced its financial results for the first quarter of fiscal year 2027, reporting a 13% increase in consolidated net revenue to $81.2 million. This growth was driven by contributions from all business segments, including significant increases in Canada medical cannabis and international markets. The company also saw an improvement in its adjusted gross margin to 31% and a 59% reduction in its Adjusted EBITDA loss year-over-year. Management expressed confidence in the continued momentum and strategies to deliver further growth, anticipating additional financial improvements in the second half of fiscal 2027.
Key Highlights
- 1
Canopy Growth reported consolidated net revenue of $81.2 million in Q1 FY2027, marking a 13% increase compared to the prior-year period.
- 2
Net revenue growth was observed across all business segments, with Canada medical cannabis up 22%, Canada adult-use cannabis up 10%, international markets cannabis up 10%, and Storz & Bickel up 6%.
- 3
Adjusted gross margin improved to 31% in Q1 FY2027 from 25% in Q1 FY2026, driven by higher sales and cost rationalization.
- 4
The Adjusted EBITDA loss narrowed by 59% year-over-year, reaching $3.2 million in Q1 FY2027 compared to $7.9 million in Q1 FY2026.
- 5
Net loss for Q1 FY2027 was significantly lower, down 68% compared to the same period in the previous fiscal year.
- 6
The company improved its adult-use market ranking to #6 overall in Canada, holding top positions in premium flower, infused pre-rolls, and oils & softgels.
Management Comments
Luc Mongeau
The renewed focus and strong momentum we established over the past year have continued into fiscal 2027. In the first quarter, we achieved net revenue growth in every business through solid execution across the organization. We have clear strategies to deliver further growth in each of our end markets. At the heart of our cannabis strategy is our company-wide push to elevate cultivation and produce a consistent and increasing supply of high-quality flower that will support growing demand both in Canada and internationally.
Tom Stewart
The combination of top-line growth and disciplined cost management is enabling us to make steady progress on key profitability measures including gross margin and adjusted EBITDA. As expected, the integration of MTL Cannabis is leading to increased supply of high-quality flower, expanded revenue opportunities and the realization of meaningful synergies. We anticipate further improvements in our financial results, especially in the second half of fiscal 2027, as the integration is completed.
Informational and educational content only. Not investment advice.